In the present study, we challenged these findings and generated a DKO strategy in which Pnpla3 deletion would be accompanied by Mgl ablation to investigate their roles in NAFLD. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.